Collegium Pharmaceutical's low ROE, despite high debt, refle...
Collegium Pharmaceutical's low ROE, despite high debt, reflects negatively on its profitability. The firm's reliance on hefty debt to boost returns poses potential risks.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more